Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.27 USD
+2.17 (2.03%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $109.28 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 109.27 +2.17(2.03%)
Will JAZZ be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Other News for JAZZ
Jazz Pharmaceuticals: Cheap But Complicated
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views